Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Precision Drilling
PDS
5
Lantheus
LNTH
US OptionsDetailed Quotes
NAMS250516P7500
- 0.00
- 0.000.00%
15min DelayClose May 9 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV59.17%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.75Leverage Ratio--Theta--Rho--Eff Leverage--Vega
NewAmsterdam Pharma Newsroom
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), GH Research (GHRS) and NewAmsterdam Pharma Company (NAMS)
Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $40
NewAmsterdam Pharma Co Analyst Ratings
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
NewAmsterdam Pharma Company (NAMS) Receives a Buy From TD Cowen
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $42
NewAmsterdam Pharma Price Target Maintained With a $42.00/Share by Needham
NewAmsterdam Pharma Co Analyst Ratings
William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
William Blair Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
NewAmsterdam Pharma Company (NAMS) Gets a Buy From Piper Sandler
Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $41
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Organogenesis Holdings (ORGO)
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Cuts Target Price to $38
NewAmsterdam Pharma Is Maintained at Sector Outperform by Scotiabank
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
